Gefitinib Eg

Gefitinib Eg is an oral medication used to treat certain types of cancer. It works by targeting specific proteins in cancer cells to slow their growth. This medication is manufactured by Eg Labo Laboratoires Eurogenerics.

Gefitinib Eg is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is designed for patients whose tumors have specific genetic features, such as mutations in the EGFR gene. This medication is part of a class of drugs known as tyrosine kinase inhibitors, which interfere with the growth and spread of cancer cells.

Common effects of Gefitinib Eg may include skin rash, diarrhea, and dry skin. Some users may also experience appetite loss, nausea, and fatigue. These effects vary among individuals and are not experienced by everyone who takes the medication.

Gefitinib Eg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication may not be suitable for everyone, and potential users should discuss their medical history and current medications with a healthcare provider before starting treatment.

Gefitinib Eg may interact with certain medications, including those that are metabolized by the liver's cytochrome P450 enzymes. It is advisable to avoid grapefruit and grapefruit juice, as they can affect how the body processes this medication. Always inform healthcare providers about all medications and supplements being taken to avoid potential interactions.